Merck (NYSE:MRK) received Japanese approval for KEYTRUDA QLEX (KEYJECT), its first subcutaneous KEYTRUDA formulation, for all ...

Week Range: $78 to $157Market Cap: around $367 billionStreet Mean Target: around $154Forward 2-Year Revenue Growth (CAGR): around 4%NTM EV/EBITDA: around 17xLTM Gross Margin: 75. 9%Dividend Yield: 2.

Merck’s MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company’s total ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

Merck (MRK) has secured Japanese regulatory approval for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection, covering all indications currently approved for ...

The medicines Merck sells today grew at their usual pace. What investors spent the year repricing was everything that comes next.

Merck (NYSE:MRK) extends a monthly rally on Keytruda strength, encouraging melanoma trial results with Moderna, and a newly accepted regulatory submission expanding its RSV therapy indication.

Merck (MRK) said that an analysis of a phase 3 trial found that treatment with Keytruda (pembrolizumab) led to a significant improvement in overall survival regardless of an ovarian cancer patient's ...

Inhibrx Biosciences (INBX) stock gains as cancer therapy INBRX-106 with Merck (MRK) Keytruda outperforms the blockbuster drug in a mid-stage trial. Read more here.